

Corporate Profile

Sino Biopharmaceutical Limited (the “Company”), together with its subsidiaries and a jointly-controlled entity (the “Group”), is an integrated pharmaceutical enterprise. The Group researches and develops, manufactures and markets a vast array of biopharmaceuticals, modernised Chinese medicines and chemical medicines by applying advanced biotechnology and modernised Chinese medicinal technology.

The Group focuses on the development and commercialisation of products in four core therapeutic categories: cardio cerebral diseases, hepatitis, ophthalmic diseases and osteoarthritis. Principal products include:

Cardio cerebral medicines: Alprostadiol injections and Spring injections

Hepatitis medicines: Diammonium Glycyrrhizinate injections and capsules, Tianqingfuxin injections and capsules

Ophthalmic medicines: Moisten eyedrops and Mioclear eyedrops


Osteoarthritis medicines: Sofast injections

The Group manufactures medicines in 14 dosage forms, each with Good Manufacturing Practices (“GMP”) certification issued by the State Food and Drug Administration (“SFDA”) of the People’s Republic of China (“PRC”). They are: large volume injections; small volume injections; powder injections; eye drops; ointments; tablets; capsules; eye ointments; nose drops; ear drops; powdered medicines; granulated medicines; PVC-free soft bags for intravenous injections; and liniment.

Website: www.sino-biopharm.com

Stock code: 1177

GROUP STRUCTURE



* 20.4% shareholding directly held by the Group and 51% shareholding indirectly held by Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.